Synta Pharmaceuticals Corporation

Fuji Immunopharmaceuticals Corp.

Yaming Wu

Lijun Sun

Shoujun Chen

Keizo Koya

Mitsunori Ono

Noriaki Tatsuta

Zhenjian Du

Weiwen Ying

Jun Jiang

Kevin Paul Foley

Hao Li

Zhi-Qiang Xia

Christopher Borella

Stephen D Gillies

Kin-Ming Lo

Hiroshi Kitaguchi

Teresa Przewloka

Elena Kostik

Takayo Inoue

Mei Zhang

Yumiko Wada

Dan Zhou

Ryoichi Nemori

Guiqing Liang

Timothy Korbut

Yumiko Jimbo

Disclosed is a compound represented by the Structural Formula (I):  Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with Paclitaxel or an analog of Paclitaxel.

Paclitaxel enhancer compounds

The invention relates to compounds of structural formula (I): 

Compounds for the treatment of proliferative disorders

One embodiment of the present invention is a method of treating a subject with a multi-drug resistant cancer. The method comprises administering to the subject an effective amount of a compound represented by Structural Formula (I): 

Treatment for cancers

One embodiment of the present invention is a compound represented by the Structural Formula (I):  Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.

Paclitaxel enhancer compound

One embodiment of the present invention is a compound represented by the Structural Formula (I):  Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both &#x3e;C&#x2550;Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or &#x2014;C(RR)&#x2014;. Ris an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, or a substituted non-aromatic heterocyclic group, R-Rare independently &#x2014;H, an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, a substituted non-aromatic heterocyclic group, an aryl group or a substituted aryl group, or Rand Rtaken together with the carbon and nitrogen atoms to which they are bonded, and/or Rand Rtaken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R-Rare independently &#x2014;H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. Rand Rare each independently &#x2014;H, an aliphatic or substituted aliphatic group, or Ris &#x2014;H and Ris a substituted or unsubstituted aryl group, or, Rand R, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is &#x2550;O or &#x2550;S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.

Disclosed is a compound represented by the Structural Formula (I): 

Taxol enhancer compounds

One embodiment of the present invention is a compound represented by the Structural Formula (I): Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both &#x3e;C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or &#x2014;C(RR)&#x2014;. Ris an aliphatic group, a substituted aliphatic group, a non-aromatic hetereocyclic group, or a substituted non-aromatic hetereocyclic group, R&#x2013;Rare independently &#x2014;H, an aliphatic group, a substituted aliphatic group, a non-aromatic hetereocyclic group, a substituted non-aromatic hetereocyclic group, an aryl group or a substituted aryl group, or Rand Rtaken together with the carbon and nitrogen atoms to which they are bonded, and/or Rand Rtaken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R&#x2013;Rare independently &#x2014;H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. Rand Rare each independently &#x2014;H, an aliphatic or substituted aliphatic group, or Ris &#x2014;H and Ris a substituted or unsubstituted aryl group, or, Rand R, taken together, are a C2&#x2013;C6 substituted or unsubstituted alkylene group. Z is &#x2550;O or &#x2550;S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.

Disclosed is a compound represented by the Structural Formula (I): Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with taxol or an analog of taxol.

Growing community of inventors

Lexington, MA, United States of America

Yaming Wu